Tango Therapeutics Statistics Share Statistics Tango Therapeutics has 111.26M
shares outstanding. The number of shares has increased by 1.17%
in one year.
Shares Outstanding 111.26M Shares Change (YoY) 1.17% Shares Change (QoQ) 0.26% Owned by Institutions (%) 78.04% Shares Floating 65.98M Failed to Deliver (FTD) Shares 2,184 FTD / Avg. Volume 0.11%
Short Selling Information The latest short interest is 25.16M, so 23.21% of the outstanding
shares have been sold short.
Short Interest 25.16M Short % of Shares Out 23.21% Short % of Float 27.99% Short Ratio (days to cover) 13.38
Valuation Ratios The PE ratio is -2.59 and the forward
PE ratio is -4.54.
Tango Therapeutics's PEG ratio is
-0.25.
PE Ratio -2.59 Forward PE -4.54 PS Ratio 8.02 Forward PS 97.2 PB Ratio 1.69 P/FCF Ratio -2.55 PEG Ratio -0.25
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Tango Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 6.98,
with a Debt / Equity ratio of 0.18.
Current Ratio 6.98 Quick Ratio 6.98 Debt / Equity 0.18 Debt / EBITDA -0.26 Debt / FCF -0.28 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $271.41K Profits Per Employee $-840.66K Employee Count 155 Asset Turnover 0.13 Inventory Turnover n/a
Taxes Income Tax 208K Effective Tax Rate -0.16%
Stock Price Statistics The stock price has increased by -31.6% in the
last 52 weeks. The beta is 1.65, so Tango Therapeutics's
price volatility has been higher than the market average.
Beta 1.65 52-Week Price Change -31.6% 50-Day Moving Average 6.56 200-Day Moving Average 3.62 Relative Strength Index (RSI) 53.44 Average Volume (20 Days) 1,987,503
Income Statement In the last 12 months, Tango Therapeutics had revenue of 42.07M
and earned -130.3M
in profits. Earnings per share was -1.19.
Revenue 42.07M Gross Profit 42.07M Operating Income -145.59M Net Income -130.3M EBITDA -143.1M EBIT -145.59M Earnings Per Share (EPS) -1.19
Full Income Statement Balance Sheet The company has 69.53M in cash and 36.49M in
debt, giving a net cash position of 33.04M.
Cash & Cash Equivalents 69.53M Total Debt 36.49M Net Cash 33.04M Retained Earnings -501.56M Total Assets 237.89M Working Capital 150.07M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -131.5M
and capital expenditures -754K, giving a free cash flow of -132.25M.
Operating Cash Flow -131.5M Capital Expenditures -754K Free Cash Flow -132.25M FCF Per Share -1.21
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -346.09% and -309.73%.
Gross Margin 100% Operating Margin -346.09% Pretax Margin -309.24% Profit Margin -309.73% EBITDA Margin -340.15% EBIT Margin -346.09% FCF Margin -314.38%
